All patients with HER2-positive early and locally advanced breast cancer that are candidates for adjuvant systemic therapy are also candidates for neoadjuvant systemic anti-HER2 therapy [8] regardless of tumor size, especially in the following cases:. The gene discussed is ERBB2; the disease is breast carcinoma.